12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
NCT00456586
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
180
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
KW-6002 (istradefylline)
Sponsor
Kyowa Kirin, Inc.